NICE has endorsed the use of ibrutinib in combination therapy for untreated mantle cell lymphoma, providing a new alternative to transplant-based first-line treatments. This decision marks a significant shift in treatment options for patients with this aggressive form of lymphoma.

A recent study highlights a rare paraneoplastic syndrome where mantle cell lymphoma manifests as bullous pemphigoid. This discovery may enhance understanding of the relationship between hematological malignancies and autoimmune skin disorders.

NICE has approved new combination regimens involving Acalabrutinib for chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). This decision enhances treatment options for patients with these blood cancers.

BeOne's Beqalzi becomes the first BCL2 inhibitor approved for relapsed or refractory mantle cell lymphoma, marking a significant advancement in treatment options for this patient population. This approval opens the door for new therapeutic strategies in managing this challenging disease.

FDA announces the initiation of proof-of-concept real-time clinical trials (RTCTs) by AstraZeneca and Amgen, aiming to accelerate drug development. AstraZeneca's Phase 2 trial, TRAVERSE, targets treatment-naïve mantle cell lymphoma and involves collaboration with leading cancer centers.